128 related articles for article (PubMed ID: 8235308)
1. Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro.
Hatano T; Ohkawa K; Matsuda M
Tumour Biol; 1993; 14(5):288-94. PubMed ID: 8235308
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro.
Ohkawa K; Hatano T; Tsukada Y; Matsuda M
Br J Cancer; 1993 Feb; 67(2):274-8. PubMed ID: 8431358
[TBL] [Abstract][Full Text] [Related]
3. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma.
Ohkawa K; Hatano T; Yamada K; Joh K; Takada K; Tsukada Y; Matsuda M
Cancer Res; 1993 Sep; 53(18):4238-42. PubMed ID: 8364920
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells.
Wang F; Jiang X; Yang DC; Elliott RL; Head JF
Anticancer Res; 2000; 20(2A):799-808. PubMed ID: 10810357
[TBL] [Abstract][Full Text] [Related]
5. Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models.
Ishima Y; Hara M; Kragh-Hansen U; Inoue A; Suenaga A; Kai T; Watanabe H; Otagiri M; Maruyama T
J Control Release; 2012 Nov; 164(1):1-7. PubMed ID: 23063551
[TBL] [Abstract][Full Text] [Related]
6. Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells.
Asakura T; Takahashi N; Takada K; Inoue T; Ohkawa K
Anticancer Drugs; 1997 Feb; 8(2):199-203. PubMed ID: 9073316
[TBL] [Abstract][Full Text] [Related]
7. Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR.
Solary E; Velay I; Chauffert B; Caillot D; Bidan JM; Dumas M; Casasnovas O; Guy H
Nouv Rev Fr Hematol (1978); 1990; 32(5):361-3. PubMed ID: 2099412
[TBL] [Abstract][Full Text] [Related]
8. Transferrin as a drug carrier: Cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells.
Szwed M; Matusiak A; Laroche-Clary A; Robert J; Marszalek I; Jozwiak Z
Toxicol In Vitro; 2014 Mar; 28(2):187-97. PubMed ID: 24055890
[TBL] [Abstract][Full Text] [Related]
9. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of a transferrin-adriamycin conjugate to anthracycline-resistant cells.
Fritzer M; Barabas K; Szüts V; Berczi A; Szekeres T; Faulk WP; Goldenberg H
Int J Cancer; 1992 Oct; 52(4):619-23. PubMed ID: 1399145
[TBL] [Abstract][Full Text] [Related]
12. Combined activity of interleukin-1 alpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects.
Borsellino N; Crescimanno M; Flandina C; Flugy A; D'Alessandro N
Anticancer Res; 1994; 14(6B):2643-8. PubMed ID: 7872695
[TBL] [Abstract][Full Text] [Related]
13. Glutathione-doxorubicin conjugate expresses potent cytotoxicity by suppression of glutathione S-transferase activity: comparison between doxorubicin-sensitive and -resistant rat hepatoma cells.
Asakura T; Ohkawa K; Takahashi N; Takada K; Inoue T; Yokoyama S
Br J Cancer; 1997; 76(10):1333-7. PubMed ID: 9374380
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-peptide conjugates overcome multidrug resistance.
Mazel M; Clair P; Rousselle C; Vidal P; Scherrmann JM; Mathieu D; Temsamani J
Anticancer Drugs; 2001 Feb; 12(2):107-16. PubMed ID: 11261883
[TBL] [Abstract][Full Text] [Related]
15. Circumvention of acquired resistance to doxorubicin in K562 human leukemia cells by oxatomide.
Ishikawa M; Fujita R; Furusawa S; Takayanagi M; Sasaki K; Satoh S
Biol Pharm Bull; 2001 Oct; 24(10):1185-7. PubMed ID: 11642329
[TBL] [Abstract][Full Text] [Related]
16. Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy.
Kratz F; Beyer U; Roth T; Tarasova N; Collery P; Lechenault F; Cazabat A; Schumacher P; Unger C; Falken U
J Pharm Sci; 1998 Mar; 87(3):338-46. PubMed ID: 9523988
[TBL] [Abstract][Full Text] [Related]
17. Combinative growth-inhibitory effects of interferon-alpha and Doxorubicin on multidrug-resistant tumor-cell lines.
Leonardi V; Borsellino N; Crescimanno M; Flandina C; Flugy A; Dalessandro N
Oncol Rep; 1994 Jan; 1(1):161-4. PubMed ID: 21607328
[TBL] [Abstract][Full Text] [Related]
18. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the cytotoxicity and selectivity of doxorubicin to hepatoma cells by synergistic combination of galactose-decorated γ-poly(glutamic acid) nanoparticles and low-intensity ultrasound.
Tsai WB; Lai HY; Lee JL; Lo CW; Chen WS
Langmuir; 2014 May; 30(19):5510-7. PubMed ID: 24754730
[TBL] [Abstract][Full Text] [Related]
20. Relationship between cytocidal activity and glutathione-S-transferase inhibition using doxorubicin coupled to stereoisomers of glutathione with different substrate specificity.
Hashizume Y; Asakura T; Oikawa T; Yamauchi T; Soda K; Ohkawa K
Anticancer Drugs; 2001 Jul; 12(6):549-54. PubMed ID: 11460002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
